Cargando…

S100B as an Antagonist To Interfere with the Interface Area Flanked by S100A11 and RAGE V Domain

[Image: see text] The Ca(2+)-sensing protein S100A11 of the S100 family is an important mediator of numerous biological functions and pathological conditions including cancer. The receptor for advanced glycation end products (RAGE) has been well accepted as the major receptor for several S100 family...

Descripción completa

Detalles Bibliográficos
Autores principales: Dowarha, Deepu, Chou, Ruey-Hwang, Yu, Chin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2018
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6644751/
https://www.ncbi.nlm.nih.gov/pubmed/31459098
http://dx.doi.org/10.1021/acsomega.8b00922
_version_ 1783437319225737216
author Dowarha, Deepu
Chou, Ruey-Hwang
Yu, Chin
author_facet Dowarha, Deepu
Chou, Ruey-Hwang
Yu, Chin
author_sort Dowarha, Deepu
collection PubMed
description [Image: see text] The Ca(2+)-sensing protein S100A11 of the S100 family is an important mediator of numerous biological functions and pathological conditions including cancer. The receptor for advanced glycation end products (RAGE) has been well accepted as the major receptor for several S100 family members. Here, we take the S100B protein as an antagonist to interfere with the interaction flanked by S100A11 and the RAGE V domain. We employed NMR spectroscopy to describe the interactions between the S100A11 and S100B proteins. (1)H–(15)N heteronuclear single-quantum correlation-NMR titrations showed the potential binding dynamics of S100A11 and S100B interactions. In the HADDOCK program, we constructed the S100A11–S100B heterodimer complex that was then superimposed with the S100A11–S100B complex structure in the same orientation as the S100A11–RAGE V domain complex. This overlay analysis showed that S100B could interfere in the binding section of S100A11 and the RAGE V domain. Additionally, water-soluble tetrazolium-1 assay provided a functional read-out of the effects of these proteins in an in vitro cancer model. Our study establishes that the development of an S100B antagonist could perform a vital part in the treatment of S100- and RAGE-dependent human diseases.
format Online
Article
Text
id pubmed-6644751
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-66447512019-08-27 S100B as an Antagonist To Interfere with the Interface Area Flanked by S100A11 and RAGE V Domain Dowarha, Deepu Chou, Ruey-Hwang Yu, Chin ACS Omega [Image: see text] The Ca(2+)-sensing protein S100A11 of the S100 family is an important mediator of numerous biological functions and pathological conditions including cancer. The receptor for advanced glycation end products (RAGE) has been well accepted as the major receptor for several S100 family members. Here, we take the S100B protein as an antagonist to interfere with the interaction flanked by S100A11 and the RAGE V domain. We employed NMR spectroscopy to describe the interactions between the S100A11 and S100B proteins. (1)H–(15)N heteronuclear single-quantum correlation-NMR titrations showed the potential binding dynamics of S100A11 and S100B interactions. In the HADDOCK program, we constructed the S100A11–S100B heterodimer complex that was then superimposed with the S100A11–S100B complex structure in the same orientation as the S100A11–RAGE V domain complex. This overlay analysis showed that S100B could interfere in the binding section of S100A11 and the RAGE V domain. Additionally, water-soluble tetrazolium-1 assay provided a functional read-out of the effects of these proteins in an in vitro cancer model. Our study establishes that the development of an S100B antagonist could perform a vital part in the treatment of S100- and RAGE-dependent human diseases. American Chemical Society 2018-08-22 /pmc/articles/PMC6644751/ /pubmed/31459098 http://dx.doi.org/10.1021/acsomega.8b00922 Text en Copyright © 2018 American Chemical Society This is an open access article published under an ACS AuthorChoice License (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html) , which permits copying and redistribution of the article or any adaptations for non-commercial purposes.
spellingShingle Dowarha, Deepu
Chou, Ruey-Hwang
Yu, Chin
S100B as an Antagonist To Interfere with the Interface Area Flanked by S100A11 and RAGE V Domain
title S100B as an Antagonist To Interfere with the Interface Area Flanked by S100A11 and RAGE V Domain
title_full S100B as an Antagonist To Interfere with the Interface Area Flanked by S100A11 and RAGE V Domain
title_fullStr S100B as an Antagonist To Interfere with the Interface Area Flanked by S100A11 and RAGE V Domain
title_full_unstemmed S100B as an Antagonist To Interfere with the Interface Area Flanked by S100A11 and RAGE V Domain
title_short S100B as an Antagonist To Interfere with the Interface Area Flanked by S100A11 and RAGE V Domain
title_sort s100b as an antagonist to interfere with the interface area flanked by s100a11 and rage v domain
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6644751/
https://www.ncbi.nlm.nih.gov/pubmed/31459098
http://dx.doi.org/10.1021/acsomega.8b00922
work_keys_str_mv AT dowarhadeepu s100basanantagonisttointerferewiththeinterfaceareaflankedbys100a11andragevdomain
AT chourueyhwang s100basanantagonisttointerferewiththeinterfaceareaflankedbys100a11andragevdomain
AT yuchin s100basanantagonisttointerferewiththeinterfaceareaflankedbys100a11andragevdomain